

UPNEEQ[®]


(oxymetazoline hydrochloride ophthalmic solution), 0.1%*

*Each mL of Upneeq contains 1 mg of oxymetazoline hydrochloride, equivalent to 0.09 mg (0.09%) of oxymetazoline free base.

Give Ptosis Patients an EYE-OPENING Lift With a Daily Drop of Upneeq^{®1}

The only FDA-approved prescription eyedrop proven to raise upper eyelids in adults with acquired blepharoptosis (low-lying lids)¹

Examples of positive results after the first dose of Upneeq



Images are of actual patients. Individual results may vary. Average upper eyelid lift with Upneeq in clinical trials was 1mm.*²

*Two randomized, multicenter, double-masked, vehicle-controlled, Phase 3 studies compared once-daily Upneeq in 304 subjects with acquired blepharoptosis. Efficacy was assessed with the Leicester Peripheral Field Test (LPFT) and photographic measurement of Marginal Reflex Distance (MRD1). There was a statistically significant difference in mean change in the LPFT from baseline after instillation of Upneeq and vehicle, with significantly greater increases in the study eye of the Upneeq group evident at the 2-hour point and maintained at the 6-hour time point. Greater MRD1 increases were observed for the Upneeq group than the vehicle group on Day 1 at 6 hours post-dose and on Day 14 at 2 hours post-dose.¹

IMPORTANT SAFETY INFORMATION

INDICATION

Upneeq[®] (oxymetazoline hydrochloride ophthalmic solution), 0.1% is indicated for the treatment of acquired blepharoptosis in adults.

WARNINGS AND PRECAUTIONS

- Alpha-adrenergic agonists as a class may impact blood pressure. Advise Upneeq patients with cardiovascular disease, orthostatic hypotension, and/or uncontrolled hypertension or hypotension to seek medical care if their condition worsens.

Please see Important Safety Information continued on next page.

Please see accompanying full Prescribing Information and Patient Information.

UPNEEQ[®]

(oxymetazoline hydrochloride
ophthalmic solution), 0.1%

Modernizing prescription access by removing insurance restrictions

Treatment with Upneeq[®] is a choice between you and your patient

- Free of traditional hassles such as Prior Authorizations, Step Edits, and Callbacks
- The cost of Upneeq only varies by quantity but is the same for all patients
 - ◇ 30-day supply is \$105

Upneeq is available exclusively through RVL Pharmacy

- Our friendly and knowledgeable pharmacy staff will contact patients, process Upneeq prescriptions, and facilitate delivery to their home or preferred destination

ePrescribe				
Select RVL Pharmacy in your EMR:				
Location	NPI	NCPDP	Fax Number	Phone Number
Sayreville, NJ 08872	1770193757	3157369	844-567-3937	844-RVL-EYES (844-785-3937)

WARNINGS AND PRECAUTIONS

- Use Upneeq with caution in patients with cerebral or coronary insufficiency or Sjögren's syndrome. Advise patients to seek medical care if signs and symptoms of potentiation of vascular insufficiency develop.
- Upneeq may increase the risk of angle closure glaucoma in patients with untreated narrow-angle glaucoma. Advise patients to seek immediate medical care if signs and symptoms of acute narrow-angle glaucoma develop.
- Patients should not touch the tip of the single patient-use container to their eye or to any surface, in order to avoid eye injury or contamination of the solution.

ADVERSE REACTIONS

Adverse reactions that occurred in 1-5% of subjects treated with Upneeq were punctate keratitis, conjunctival hyperemia, dry eye, blurred vision, instillation site pain, eye irritation, and headache.

DRUG INTERACTIONS

- Alpha-adrenergic agonists, as a class, may impact blood pressure. Caution in using drugs such as beta blockers, anti-hypertensives, and/or cardiac glycosides is advised. Caution should also be exercised in patients receiving alpha adrenergic receptor antagonists such as in the treatment of cardiovascular disease, or benign prostatic hypertrophy.
- Caution is advised in patients taking monoamine oxidase inhibitors which can affect the metabolism and uptake of circulating amines.

To report SUSPECTED ADVERSE REACTIONS or product complaints, contact RVL Pharmaceuticals at 1-877-482-3788. You may also report SUSPECTED ADVERSE REACTIONS to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see accompanying full Prescribing Information and Patient Information.

References: 1. Upneeq[®] (oxymetazoline hydrochloride ophthalmic solution), 0.1%. [Prescribing Information]. 2. Data on file. RVL Pharmaceuticals, Inc.

Distributed by: RVL Pharmaceuticals, Inc.
Bridgewater, NJ 08807
Customer Service 1-866-600-4799

RVL
PHARMACEUTICALS, INC.

Upneeq is a registered trademark
of RVL Pharmaceuticals, Inc.
©2021 RVL Pharmaceuticals, Inc.
PM-US-UPN-0067-2 01/21

Learn more at
Upneeq.com

